HRP20050569A2 - Haplotype partitioning in the proximal promoter of the human growth hormone (gh1) gene - Google Patents
Haplotype partitioning in the proximal promoter of the human growth hormone (gh1) gene Download PDFInfo
- Publication number
- HRP20050569A2 HRP20050569A2 HR20050569A HRP20050569A HRP20050569A2 HR P20050569 A2 HRP20050569 A2 HR P20050569A2 HR 20050569 A HR20050569 A HR 20050569A HR P20050569 A HRP20050569 A HR P20050569A HR P20050569 A2 HRP20050569 A2 HR P20050569A2
- Authority
- HR
- Croatia
- Prior art keywords
- gene
- growth hormone
- proximal promoter
- region
- snps
- Prior art date
Links
- 102000054766 genetic haplotypes Human genes 0.000 title claims description 164
- 108090000623 proteins and genes Proteins 0.000 title claims description 60
- 238000000638 solvent extraction Methods 0.000 title description 3
- 102000002265 Human Growth Hormone Human genes 0.000 title 1
- 108010000521 Human Growth Hormone Proteins 0.000 title 1
- 239000000854 Human Growth Hormone Substances 0.000 title 1
- 230000014509 gene expression Effects 0.000 claims description 87
- 108010051696 Growth Hormone Proteins 0.000 claims description 79
- 239000000122 growth hormone Substances 0.000 claims description 79
- 230000000694 effects Effects 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 26
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 21
- 230000004064 dysfunction Effects 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 10
- 230000012010 growth Effects 0.000 claims description 9
- 108091026890 Coding region Proteins 0.000 claims description 8
- 230000009261 transgenic effect Effects 0.000 claims description 8
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 230000003321 amplification Effects 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 238000002405 diagnostic procedure Methods 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 230000008092 positive effect Effects 0.000 claims description 3
- 238000012408 PCR amplification Methods 0.000 claims description 2
- 239000012474 protein marker Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 102000018997 Growth Hormone Human genes 0.000 claims 17
- 102100038803 Somatotropin Human genes 0.000 description 62
- 210000004027 cell Anatomy 0.000 description 38
- 108700028369 Alleles Proteins 0.000 description 37
- 101150009271 gh1 gene Proteins 0.000 description 22
- 239000013615 primer Substances 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 15
- 239000012634 fragment Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 108060001084 Luciferase Proteins 0.000 description 11
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 11
- 239000005089 Luciferase Substances 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 230000001817 pituitary effect Effects 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 7
- 229920003266 Leaf® Polymers 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 101150054854 POU1F1 gene Proteins 0.000 description 6
- 108700008625 Reporter Genes Proteins 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 108091023040 Transcription factor Proteins 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 101100149846 Homo sapiens GH1 gene Proteins 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 101150055782 gH gene Proteins 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 2
- 102100038530 Chorionic somatomammotropin hormone 2 Human genes 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100036717 Growth hormone variant Human genes 0.000 description 2
- 101000895818 Homo sapiens Chorionic somatomammotropin hormone 1 Proteins 0.000 description 2
- 101000956228 Homo sapiens Chorionic somatomammotropin hormone 2 Proteins 0.000 description 2
- 101000642577 Homo sapiens Growth hormone variant Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000007476 Maximum Likelihood Methods 0.000 description 2
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101100540673 Rattus norvegicus Gc gene Proteins 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000009699 differential effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 230000006916 protein interaction Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000003718 Dual-Luciferase Reporter Assay System Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 description 1
- 101000687438 Homo sapiens Prolactin Proteins 0.000 description 1
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101150083321 Nf1 gene Proteins 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010003044 Placental Lactogen Proteins 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- 238000003646 Spearman's rank correlation coefficient Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108700020942 nucleic acid binding protein Proteins 0.000 description 1
- 102000044158 nucleic acid binding protein Human genes 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0229725.7A GB0229725D0 (en) | 2002-12-19 | 2002-12-19 | Haplotype partitioning and growth hormone SNPs |
| GB0306417A GB0306417D0 (en) | 2003-03-20 | 2003-03-20 | Haplotype partitioning in the proximal promoter of the human growth hormone (GH1) gene |
| GB0308240A GB0308240D0 (en) | 2003-04-10 | 2003-04-10 | Haplotype partitioning in the proximal promoter of the human growth hormone (GH1) gene |
| PCT/GB2003/005405 WO2004057028A1 (en) | 2002-12-19 | 2003-12-11 | Haplotype partitioning in the proximal promoter of the human growth hormone (gh1) gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20050569A2 true HRP20050569A2 (en) | 2005-10-31 |
Family
ID=32512062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20050569A HRP20050569A2 (en) | 2002-12-19 | 2005-06-17 | Haplotype partitioning in the proximal promoter of the human growth hormone (gh1) gene |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20040110173A1 (no) |
| EP (1) | EP1573060A1 (no) |
| JP (1) | JP2004290173A (no) |
| KR (1) | KR20040054472A (no) |
| AU (2) | AU2003203781A1 (no) |
| CA (1) | CA2423904A1 (no) |
| HR (1) | HRP20050569A2 (no) |
| NO (1) | NO20053489L (no) |
| NZ (1) | NZ525314A (no) |
| WO (1) | WO2004057028A1 (no) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0600116D0 (en) * | 2006-01-05 | 2006-02-15 | Univ Cardiff | Allele-specific sequencing |
| CN114250279B (zh) * | 2020-09-22 | 2024-04-30 | 上海韦翰斯生物医药科技有限公司 | 一种单倍型的构建方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1568772T3 (da) * | 1995-09-21 | 2010-10-18 | Genentech Inc | Varianter af humant væksthormon |
| CA2197408A1 (en) * | 1996-02-13 | 1997-08-14 | Kazuo Chihara | Mutant human growth hormones and their uses |
| GB0011459D0 (en) * | 2000-05-12 | 2000-06-28 | Univ Wales Medicine | Sequences |
-
2003
- 2003-04-14 NZ NZ525314A patent/NZ525314A/en unknown
- 2003-04-14 CA CA002423904A patent/CA2423904A1/en not_active Abandoned
- 2003-04-17 AU AU2003203781A patent/AU2003203781A1/en not_active Abandoned
- 2003-05-20 KR KR1020030031746A patent/KR20040054472A/ko not_active Application Discontinuation
- 2003-06-11 US US10/459,184 patent/US20040110173A1/en not_active Abandoned
- 2003-08-14 JP JP2003207560A patent/JP2004290173A/ja active Pending
- 2003-12-11 EP EP03782612A patent/EP1573060A1/en not_active Withdrawn
- 2003-12-11 AU AU2003290247A patent/AU2003290247A1/en not_active Abandoned
- 2003-12-11 WO PCT/GB2003/005405 patent/WO2004057028A1/en not_active Application Discontinuation
-
2005
- 2005-06-17 HR HR20050569A patent/HRP20050569A2/hr not_active Application Discontinuation
- 2005-07-18 NO NO20053489A patent/NO20053489L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003203781A1 (en) | 2004-07-08 |
| WO2004057028A1 (en) | 2004-07-08 |
| NZ525314A (en) | 2005-02-25 |
| US20040110173A1 (en) | 2004-06-10 |
| KR20040054472A (ko) | 2004-06-25 |
| EP1573060A1 (en) | 2005-09-14 |
| JP2004290173A (ja) | 2004-10-21 |
| AU2003290247A1 (en) | 2004-07-14 |
| CA2423904A1 (en) | 2004-06-19 |
| NO20053489L (no) | 2005-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Horan et al. | Human growth hormone 1 (GH1) gene expression: complex haplotype‐dependent influence of polymorphic variation in the proximal promoter and locus control region | |
| US20020150945A1 (en) | Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis | |
| Cirera et al. | New insights into the melanophilin (MLPH) gene controlling coat color phenotypes in American mink | |
| US20050003410A1 (en) | Allele-specific expression patterns | |
| JP2009528063A (ja) | 依存症に対するマーカー | |
| Pauciullo et al. | Casein gene cluster in camelids: comparative genome analysis and new findings on haplotype variability and physical mapping | |
| Zhang et al. | Novel mutations in the Myo5a gene cause a dilute coat color phenotype in mice | |
| Yelina et al. | CRISPR targeting of MEIOTIC-TOPOISOMERASE VIB-dCas9 to a recombination hotspot is insufficient to increase crossover frequency in Arabidopsis | |
| Yu et al. | Tbx15/18/22 shares a binding site with Tbx6-rb to maintain expression of a muscle structural gene in ascidian late embryos | |
| HRP20050569A2 (en) | Haplotype partitioning in the proximal promoter of the human growth hormone (gh1) gene | |
| Blackshear et al. | Chromosomal mapping of the human (MACS) and mouse (Macs) genes encoding the MARCKS protein | |
| HRP20050568A2 (en) | Haplotype partitioning | |
| Singh et al. | From gene to genomics: tools for improvement of animals | |
| Phinchongsakuldit et al. | Evolution of developmental genes: molecular microevolution of enhancer sequences at the Ubx locus in Drosophila and its impact on developmental phenotypes | |
| WO2007059120A2 (en) | Allelic form of the hmga2 gene predisposing women to the formation of leiomyomas | |
| Otake et al. | The Y chromosome that lost the male-determining function behaves as an X chromosome in the medaka fish, Oryzias latipes | |
| Mizutani et al. | Unique mutations in mitochondrial DNA of senescence-accelerated mouse (SAM) strains | |
| Poriswanish | Recombination Behaviour and Evolutionary History of the Extended Pseudoautosomal Region 1 (ePAR) on the Human Y chromosome | |
| Hogan | Chapter 4—Principles and techniques of molecular biology | |
| CN118389698A (zh) | 一种与绵羊尾长相关的snp分子标记及其应用 | |
| Xie et al. | Synonymous with Pre-mRNA Cleavage Complex II Protein (Pcf11) in Drosophila | |
| CN108174823A (zh) | 一种孕烷x受体转基因小鼠模型、其构建方法及其应用 | |
| Kopp et al. | Transmission of human genetic disease | |
| Owen et al. | Applications to the study and treatment of Applications to the study and t'reatment of respiratory disease: methodsin molecular biology | |
| ANNEX | Total, both scxcs 1544 ‘ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20071122 Year of fee payment: 5 |
|
| OBST | Application withdrawn |